Premium
Norfloxacin: Clinical Pharmacology and Clinical Use
Author(s) -
Rowen Randall C.,
Michel Daniel J.,
Thompson Judith C.
Publication year - 1987
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1987.tb04030.x
Subject(s) - norfloxacin , nalidixic acid , microbiology and biotechnology , pseudomonas aeruginosa , pharmacology , pharmacokinetics , neisseria gonorrhoeae , staphylococcus aureus , gentamicin , antibiotics , chemistry , medicine , antibiotic resistance , bacteria , biology , ciprofloxacin , genetics
Norfloxacin, a nalidixic acid analog, is the first of the fluorinated quinolinecarboxylic acids to be marketed in the United States. It demonstrates potent antibacterial activity against aerobic, gram‐negative bacteria including the Enterobacteriaceae, gentamicin‐resistant Pseudomonas aeruginosa , and penicillin‐resistant Neisseria gonorrhoeae . Norfloxacin exhibits good activity against methicillin‐resistant and ‐sensitive Staphylococcus aureus , but less activity against most other aerobic, gram‐positive organisms. Anaerobic bacteria are resistant to the drug. Resistance to norfloxacin is not plasmid mediated, but is secondary to bacterial mutation, and occurs less frequently than nalidixic acid resistance. Its pharmacokinetic properties after a 400‐mg oral dose consist of a peak serum concentration of 1.3–1.58 μg/ml, an elimination half‐life of 3–7 hours, and good penetration into kidney and prostatic tissues. Renal excretion is the major route of elimination. Norfloxacin is highly effective in the treatment of uncomplicated and complicated urinary tract infections, and gonococcal urethritis. Adverse effects are generally well tolerated and usually do not require discontinuation of therapy.